Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Washington,	D.C.	20549	
vvasimigton,	D.O.	20070	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative
defense conditions of Rule 10b5-

1(c). See Instr	uction 10.												
1. Name and Add <u>Carter Robe</u>			2. Issuer Name and Tio Oncology Institu			, ,				O Issuer Owner er (specify			
	(First) COLOGY INS EBAKER RD #		I	3. Date of Earliest Tran 01/06/2025	saction (I	Mont	h/Day/Year)		below) below) Chief Financial Officer				
(Street) CERRITOS	CA	90703		4. If Amendment, Date	of Origina	al File	ed (Month/Da	6. Indiv Line)	<u> </u>				
(City)	(State)	(Zip)								Person			
		Table I - No	on-Derivati	ve Securities Ac	quired,	, Dis	sposed of	, or Be	eneficially	Owned			
Date			2. Transaction Date (Month/Day/Ye	Execution Date,	3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)			r. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (I 8)		5. Nu of Deriv Secul Acqu (A) or Dispo of (D) (Instr and 5	ative rities ired osed	6. Date Exercis Expiration Date (Month/Day/Yea	e	7. Title Amou Secur Under Deriva Secur 3 and	nt of ities lying ative ity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				1 1		I I				i I	Amount		I	l	I

Code ν

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

Explanation of Responses:

Class A Common Stock

1. The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.

(D)

(A)

Date

Exercisable

2. Price is the volume weighted average selling price of all sales by the Reporting Person on January 6, 2025 within a one-dollar range. Actual prices ranged from \$0.293 to \$0.335. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

Remarks:

/s/ Mark Hueppelsheuser,

Number

Shares

Title

(A) or (D)

Amount

Date

258(1)

Price

\$0.335(2)

(Instr. 3 and 4)

31,501

D

01/07/2025 Attorney-in-fact for Robert

Carter

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

01/06/2025

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.